Tandem Diabetes Care | TNDM - Des Atouts





Des Atouts Changement Date
Abbott USD 86.71B 2.53B 2025-12
Accuray USD 456.82M 13.42M 2025-09
Align Technology USD 6.23B 141K 2025-12
AtriCure USD 654.18M 18.74M 2025-12
Baxter International USD 20.06B 1.01B 2025-12
Becton, Dickinson and Co. USD 54.84B 484M 2025-12
Boston Scientific USD 43.67B 966M 2025-12
Cooper Companies USD 12.42B 29.4M 2025-12
Dexcom USD 6.34B 1.16B 2025-12
Edwards Lifesciences USD 13.27B 216.5M 2025-09
Eli Lilly USD 112.48B 2.46B 2025-12
Globus Medical USD 5.3B 207.12M 2025-12
ICU Medical USD 4.05B 52.39M 2025-12
Inogen USD 307.01M 5.03M 2025-09
Insulet USD 3.19B 161.1M 2025-12
Integra LifeSciences USD 3.6B 44.45M 2025-12
Intuitive Surgical USD 20.46B 1.11B 2025-12
J&J USD 199.21B 6.39B 2025-12
Masimo USD 1.7B 118.6M 2025-12
Medtronic USD 91.48B 139M 2025-12
Merit Medical Systems USD 2.69B 54.92M 2025-12
Orthofix International USD 850.65M 18.04M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Stryker USD 47.84B 787M 2025-12
Tandem Diabetes Care USD 881.11M 6.46M 2025-12
Teleflex USD 6.95B 924.7M 2025-12
Zimmer Biomet Holdings USD 23.09B 396.3M 2025-12